Table 1.
Baseline characteristics of the modified intention-to-treat population.
| Characteristics | Hybutimibe plus atorvastatin (n = 128) | Atorvastatin (n = 125) | P |
|---|---|---|---|
| Age, years | 62.12 ± 6.37 | 60.89 ± 7.79 | 0.1714 |
| Sex, Males | 79 (61.72) | 78 (62.40) | 0.9111 |
| BMI, kg/m2 | 25.24 ± 3.21 | 25.63 ± 3.09 | 0.3278 |
| Comorbidity | 0.5774 | ||
| Coronary heart disease | 90 (70.31) | 88 (70.40) | |
| Stroke | 30 (23.44) | 21 (16.80) | |
| Diabetes | 62 (48.44) | 55 (44.00) | |
| SBP, mmHg | 127.73 ± 11.66 | 127.72 ± 10.73 | 0.9919 |
| DBP, mmHg | 76.40 ± 8.52 | 77.74 ± 8.28 | 0.2066 |
| Heart rate, times per min | 71.97 ± 8.68 | 72.42 ± 9.05 | 0.6886 |
| Respiratory, times per min | 18.09 ± 1.33 | 18.01 ± 1.54 | 0.6668 |
| TC, mmol/L | 4.21 ± 0.45 | 4.20 ± 0.48 | 0.8317 |
| TG, mmol/L | 1.59 ± 0.61 | 1.61 ± 0.73 | 0.8017 |
| HDL-C, mmol/L | 1.24 ± 0.27 | 1.29 ± 0.31 | 0.1478 |
| LDL-C, mmol/L | 2.61 ± 0.30 | 2.58 ± 0.31 | 0.3938 |
| APO-A1, g/L | 1.37 ± 0.21 | 1.42 ± 0.23 | 0.1102 |
| APO-B, g/L | 0.89 ± 0.11 | 0.90 ± 0.11 | 0.9329 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; APO-A1, apoprotein A1; APO-B, apoprotein B.